To further demonstrate the possibility of alleviating CKD progression via targeted inhibition of JAK1, we used another specific JAK1 inhibitor, ivarmacitinib (Ivarm),52 in parallel with BLI (Figure 8A). This evidence concerns the gene JAK1 and chronic kidney disease.